New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 4, 2014
10:00 EDTAMCX, ECHO, GWPH, KIN, IMAX, SYMC, GASS, BIN, MSG, LGF, LOCK, KFX, GLYC, CJES, STRMOn The Fly: Analyst Initiation Summary
AMC Networks (AMCX) initiated with a Buy at Topeka... C&J Energy (CJES) initiated with a Buy at Jefferies... GlycoMimetics (GLYC) initiated with a Buy at Stifel... Kofax (KFX) initiated with a Buy at Craig-Hallum... LifeLock (LOCK) initiated with a Buy at Sterne Agee... Lionsgate (LGF) initiated with a Buy at Topeka... Madison Square Garden (MSG) initiated with a Buy at Topeka... Progressive Waste (BIN) initiated with an Underperform at Macquarie... StealthGas (GASS) initiated with an Overweight at Barclays... Symantec (SYMC) initiated with a Neutral at Sterne Agee... IMAX (IMAX) initiated with a Buy at CRT Capital... Kindred Biosciences (KIN) initiated with a Buy at Roth Capital... GW Pharmaceuticals (GWPH) initiated with an Outperform at Leerink... Echo Global (ECHO) initiated with a Hold at BB&T... Streamline Health (STRM) initiated with a Buy at Lake Street.
News For AMCX;CJES;GLYC;KFX;LOCK;LGF;MSG;BIN;GASS;SYMC;IMAX;KIN;GWPH;ECHO;STRM From The Last 14 Days
Check below for free stories on AMCX;CJES;GLYC;KFX;LOCK;LGF;MSG;BIN;GASS;SYMC;IMAX;KIN;GWPH;ECHO;STRM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
August 28, 2014
08:47 EDTGASSStealthGas reports Q2 adjusted EPS 12c, consensus 17c
Subscribe for More Information
07:58 EDTBINProgressive Waste upgraded to Outperform from Market Perform at BMO Capital
BMO Capital upgraded Progressive Waste to Outperform based on improving industry fundamentals, a pick up in pricing, and upside free cash flow upside form operational and capital discipline. Price target raised to $30 from $26.
06:54 EDTSYMCSymantec coverage resumed with a Hold at Stifel
05:46 EDTKFXKofax announces $450K sale of software
Subscribe for More Information
August 27, 2014
07:23 EDTECHOStephens to hold a field trip
Subscribe for More Information
August 26, 2014
08:04 EDTBINProgressive Waste renews normal course issuer bid
Progressive Waste announced that it has received approval from the Toronto Stock Exchange, or TSX, to renew, for a 12-month-period, its normal course issuer bid, or NCIB, effective August 28. In July, the company's board authorized a share repurchase program of up to $400M through December 31, 2017, to be implemented in accordance with TSX regulations, which require NCIBs to be renewed on an annual basis.
August 25, 2014
17:30 EDTMSGMadison Square Garden has more room for gains, Barron's says
Madison Square Garden has more room for gains now that JAT Capital Management took an activist stake in the company, Barron's argues in its 'Barron's Take' column. Reference Link
August 22, 2014
17:05 EDTMSGJAT Capital reports 6.73% stake in Madison Square Garden, may seek talks
JAT Capital may seek to engage with the company's board of directors or members of management of the company in a constructive manner to provide recommendations on ways to achieve long-term value for the company and influence the company through customary means including presenting their views for consideration to other stockholders, industry participants, knowledgeable industry or market observers, and other interested parties.
09:43 EDTMSGMadison Square Garden downgraded at ISI Group
As previously reported, ISI Group downgraded Madison Square Garden to Neutral from Buy. The firm downgraded shares due to valuation and mixed 2015 comps. Price target remains $66.
09:33 EDTMSGMadison Square Garden downgraded to Neutral from Buy at ISI Group
Subscribe for More Information
August 21, 2014
10:14 EDTMSGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:07 EDTKINOn The Fly: Pre-market Movers
Subscribe for More Information
08:20 EDTKINKindred Biosciences price target lowered to $19 from $30 at BMO Capital
BMO Capital cut its price target on Kindred after the company announced that its pivotal study of CereKin for the treatment of osteoarthritis in dogs did not meet its primary endpoint. However, the firm thinks that each of two other trials that the company is undertaking has a 70% chance of succeeding. The firm believes that the company has many more shots on goal, and it keeps an Outperform rating on the shares.
07:28 EDTMSGMadison Square Garden downgraded to Hold from Buy at Stifel
Subscribe for More Information
August 20, 2014
18:35 EDTKINOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTKINKindred reports pivotal field study of CereKin did not meet primary endpoint
Subscribe for More Information
16:00 EDTKINKindred Biosciences trading halted, pending news
Subscribe for More Information
07:37 EDTMSGMadison Square Garden reports Q4 EPS 15c, consensus 19c
Subscribe for More Information
August 19, 2014
15:16 EDTMSGNotable companies reporting before tomorrow's open
Subscribe for More Information
06:17 EDTSYMCSymantec turns attention to smartphones, connected devices, WSJ reports
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use